River & Mercantile Asset Management LLP Purchases Shares of 3,311 Forty Seven Inc (NASDAQ:FTSV)

Share on StockTwits

River & Mercantile Asset Management LLP purchased a new stake in Forty Seven Inc (NASDAQ:FTSV) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 3,311 shares of the company’s stock, valued at approximately $35,000.

A number of other large investors also recently made changes to their positions in the business. BlackRock Inc. grew its position in Forty Seven by 10.9% in the second quarter. BlackRock Inc. now owns 1,263,882 shares of the company’s stock valued at $13,399,000 after acquiring an additional 124,286 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Forty Seven by 2.1% in the second quarter. Price T Rowe Associates Inc. MD now owns 709,796 shares of the company’s stock worth $7,524,000 after purchasing an additional 14,591 shares in the last quarter. Citadel Advisors LLC boosted its stake in Forty Seven by 8.5% in the second quarter. Citadel Advisors LLC now owns 510,309 shares of the company’s stock worth $5,409,000 after purchasing an additional 39,871 shares in the last quarter. Vanguard Group Inc. boosted its stake in Forty Seven by 1.2% in the second quarter. Vanguard Group Inc. now owns 499,451 shares of the company’s stock worth $5,294,000 after purchasing an additional 5,741 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Forty Seven by 48.4% in the second quarter. JPMorgan Chase & Co. now owns 379,731 shares of the company’s stock worth $3,953,000 after purchasing an additional 123,921 shares in the last quarter. Hedge funds and other institutional investors own 36.17% of the company’s stock.

In other Forty Seven news, major shareholder Lightspeed Venture Partners X, purchased 625,000 shares of the stock in a transaction on Monday, July 22nd. The stock was bought at an average cost of $8.00 per share, for a total transaction of $5,000,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey W. Bird purchased 750,000 shares of the stock in a transaction on Monday, July 22nd. The stock was acquired at an average price of $8.00 per share, with a total value of $6,000,000.00. The disclosure for this purchase can be found here. 37.40% of the stock is owned by corporate insiders.

A number of research firms have commented on FTSV. ValuEngine raised Forty Seven from a “hold” rating to a “buy” rating in a research note on Friday, August 16th. HC Wainwright set a $21.00 price target on Forty Seven and gave the company a “buy” rating in a research note on Friday, July 12th. Oppenheimer cut their price target on Forty Seven from $35.00 to $20.00 in a research note on Wednesday, August 14th. Mizuho initiated coverage on Forty Seven in a research note on Wednesday, September 11th. They set a “buy” rating and a $18.00 price target on the stock. Finally, Zacks Investment Research raised Forty Seven from a “hold” rating to a “buy” rating and set a $9.00 price target on the stock in a research note on Thursday, September 12th. Nine investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average target price of $23.14.

NASDAQ FTSV opened at $5.97 on Friday. The stock has a 50-day simple moving average of $7.05 and a 200 day simple moving average of $11.28. Forty Seven Inc has a 12 month low of $5.69 and a 12 month high of $23.83.

Forty Seven (NASDAQ:FTSV) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.05). On average, equities research analysts predict that Forty Seven Inc will post -2.13 EPS for the current year.

About Forty Seven

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody.

Further Reading: Trading Stocks – What are percentage gainers?

Institutional Ownership by Quarter for Forty Seven (NASDAQ:FTSV)

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.